Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
567
-
Total 13F shares, excl. options
-
92.6M
-
Shares change
-
-1.33M
-
Total reported value, excl. options
-
$10.7B
-
Value change
-
-$221M
-
Put/Call ratio
-
0.93
-
Number of buys
-
292
-
Number of sells
-
-282
-
Price
-
$115.22
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2024
678 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2024.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 567 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.6M shares
of 99.6M outstanding shares and own 92.98% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.3M shares), VANGUARD GROUP INC (10M shares), STATE STREET CORP (5.15M shares), RENAISSANCE TECHNOLOGIES LLC (2.57M shares), Bellevue Group AG (1.86M shares), GEODE CAPITAL MANAGEMENT, LLC (1.86M shares), AQR CAPITAL MANAGEMENT LLC (1.84M shares), CITADEL ADVISORS LLC (1.76M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.68M shares), and JPMORGAN CHASE & CO (1.5M shares).
This table shows the top 567 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.